ESSENTIAL SYSTEMIC HYPERTENSION: GENETICS, CLINICS, EXPERIMENT
https://doi.org/10.15829/1560-4071-2017-10-133-139
Abstract
The lecture is focused on the exploration of genetic and physiological mechanisms of essential systemic hypertension (ESH). A very brief historic review is provided on the first clinical meanings of the ESH. Then some speculation provided, on its etiology, evolutionary-genetic roots regarding the formation of the main BP regulation systems. More detailed, the data is shown on genetic base of hypertensive conditions and ESH. Also, some discussion given on the monogenic forms of arterial hypertension and polygenic fundamentals of ESH, which is the most among hypertension conditions of human. Modern methods considered for genetic origins of ESH evaluation, and a necessity is underlined for the main etiological factors revealing — as of their interrelation for development of rational treatment and prevention methods against ESH.
About the Author
А. L. Markel
FRC Institute of Cytology and Genetics SD RAS; Novosibirsk State University
Russian Federation
Competing Interests: Конфликт интересов не заявляется
Russian Federation
Competing Interests: Конфликт интересов не заявляется
References
1. Frank E. Essentielle Hypertonie. Deutsches Archiv für Klinische Medizin 1911; 103: 397-412.
2. Koeners MP, Braam B, Joles JA. Blood pressure follows the kidney: Perinatal influences on hereditary hypertension. Organogenesis 2008; 4: 153-7.
3. Hines EA Jr., Some recent concepts concerning essential hypertension. J South Carolina 1933; 29: 186-91.
4. Schiffrin EL, Touyz RM (Editors). Hypertension. Published by Future Medicine Ltd. London, 2013, 273 pp.
5. JNC7-The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
6. Qaseem A, Wilt TJ, Rich R, et al. Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family PhysiciansPharmacologic Treatment of Hypertension in Adults. Annals of Internal Medicine 2017; 166: 430-7.
7. Rose G. Strategy of prevention: lessons from cardiovascular disease. British Medical Journal 1981; 282: 1847.
8. Markel AL. Evolutionary and Genetic Roots of Hypertensive Disease. Russian Journal of Genetics 2015; 51: 545-57 (In Russ.) Маркель АЛ. Эволюционно-генетические корни гипертонической болезни. Генетика 2015; 51: 545-57).
9. Carrera-Bastos P, O’Keefe JH, Cordain L, Lindeberg S. The western diet and lifestyle and diseases of civilization. Research Reports in Clinical Cardiology 2011; 2: 15-35.
10. Newman RW. Why man is such a sweaty and thirsty naked animal: A speculative review. Hum Biol 1970; 42: 12–27.
11. NCD Risk Factor Collaboration (NCD-RisC).Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19•1 million participants. Lancet 2017; 389: 37-55.
12. Williams B, Lacy PS, Thom SM and the CAFE Investigators, and the Anglo-Scandinavian Cardiac Outcomes Trial Investigators, and the CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-25.
13. Rosskopf D, Schürks M, Rimmbach C, Schäfers R. Genetics of arterial hypertension and hypotension. Naunyn-Schmiedeberg’s archives of pharmacology 2007; 374: 429-69.
14. Simonetti GD, Mohaupt MG, Bianchetti MG. Monogenic forms of hypertension. European Journal of Pediatrics 2012; 171: 1433-9.
15. Tobin MD, Tomaszewski M, Braund PS, et al. Common variants in genes underlying monogenic hypertension and hypotension and blood pressure in the general population. Hypertension 2008; 51: 1658-64.
16. Newton-Cheh C, Johnson T, Gateva V, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nature Genetics 2009; 41: 666-76.
17. Levy D, Ehret GB, Rice K, et al. Genome-wide association study of blood pressure and hypertension. Nature Genetics 2009; 41: 677-87.
18. International Consortium for Blood Pressure Genome-Wide Association Studies. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011; 478: 103-9.
19. Meyer TE, Shiffman D, Morrison AC, et al. GOSR2 Lys67Arg is associated with hypertension in whites. American Journal of Hypertension 2009; 22: 163-8.
20. Li N, Luo W, Juhong Z, et al. Associations between genetic variations in the FURIN gene and hypertension. BMC Medical Genetics 2010; 11: 124.
21. Mussig K, Kaltenbach S, Machicao F, et al. 17α-Hydroxylase/17, 20-lyase deficiency caused by a novel homozygous mutation (Y27Stop) in the cytochrome CYP17 Gene. The Journal of Clinical Endocrinology & Metabolism 2005; 90: 4362-5.
22. Warren HR, Evangelou E, Cabrera CP, et al. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nature Genetics 2017; 49: 403-15.
23. The SPRINT Research Group. A randomized trial of intensive versus standard bloodpressure control. New Engl J Med 2015; 373: 2103-16.
24. Favorova OO, Bashinskaya VV, Kulakova OG, et al. Genome wide association study as a method for genetic architecture analysis in polygenic diseases (by the example of multiple sclerosis). Molecular Biology 2014; 48 (4): 573-86. (In Russ.) Фаворова O.O., Башинская В.В., Кулакова О.Г., и др. Полногеномный поиск ассоциаций как метод анализа генетической архитектуры полигенных заболеваний (на примере рассеянного склероза). Молекулярная биология 2014; 48 (4): 573-86).
25. Zuk O, Hechter E, Sunyaev SR, Lander ES. The mystery of missing heritability: genetic interactions create phantom heritability. Proc Natl Acad Sci U SA 2012; 109: 1193-8.
26. Deng AY. Genetic mechanisms of polygenic hypertension: fundamental insights from experimental models. Journal of Hypertension 2015; 33: 669-80.
27. The International Consortium for blood pressure. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011; 478: 103-9.
28. Ehret GB, Caulfield MJ. Genes for blood pressure: an opportunity to understand hypertension. Eur Heart J 2013; 34: 951-61.
29. Chauvet C, Crespo K, Menard A, et al. Modularization and epistatic hierarchy determine homeostatic actions of multiple blood pressure quantitative trait loci. Hum Mol Genet 2013; 22: 4451-9.
30. Scherer U, Rimoldi SF, Sartori C, et al. Fetal programming and epigenetic mechanisms in arterial hypertension. Curr Opin Cardiol. 2015; 30: 393-7.
31. Dupont C, Armant DR, Brenner CA. Epigenetics: definition, mechanisms and clinical perspective. Semin Reprod Med 2009; 27: 351-7.
32. Mizuno M, Siddique K, Baum M, Smith SA. Prenatal programming of hypertension induces sympathetic overactivity in response to physical stress. Hypertension 2013; 61: 180-6.
33. Kunes J, Zicha J. The interaction of genetic and environmental factors in the etiology of hypertension. Physiol Res 2009; 58, Suppl. 2: S33-S41.
34. Gluckman PD, Hanson MA. Developmental origins of disease paradigm: a mechanistic and evolutionary perspective. Pediatr Res 2004; 56: 311-7.
35. Barker DJ, Osmond C, Golding J, et al. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 1989; 298: 564-7.
36. Ritz E, Amann K, Koleganova N, Benz K. Prenatal programming-effects on blood pressure and renal function. Nat Rev Nephrol 2011; 7: 137-44.
37. Zandi-Nejad K, Luyckx VA, Brenner BM. Adult hypertension and kidney disease: the role of fetal programming. Hypertension 2006; 47: 502-8.
38. Franco MC, Casarini DE, Carneiro-Ramos MS, et al. Circulating renin-angiotensin system and catecholamines in childhood: is there a role for birthweight? Clin Sci (Lond.) 2008; 114: 375-80.
39. Jackson AA, Dunn RL, Marchand MC, Langley-Evans SC. Increased systolic blood pressure in rats induced by a maternal low-protein diet is reversed by dietary supplementation with glycine. Clin Sci (Lond.) 2002; 103: 633-9.
40. Bogdarina I, Welham S, King PJ, et al. Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension. Circ Res 2007; 100: 520-6.
Supplementary files
|
|
1. Сопроводительное письмо | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(923KB)
|
Indexing metadata ▾ | |
Review
For citations:
Markel А.L. ESSENTIAL SYSTEMIC HYPERTENSION: GENETICS, CLINICS, EXPERIMENT. Russian Journal of Cardiology. 2017;(10):133-139. (In Russ.) https://doi.org/10.15829/1560-4071-2017-10-133-139
Views:
2097
Email this article 